Loading
A phase 3 trial of Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, Capecitabine and Cisplatin in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer is a phase 3 interventional study registered as NCT06764875 by AstraZeneca, with 840 participants planned, started 2025-03-01 and due to reach its primary completion in 2029-04-27. Interventions recorded: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil and Capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Rilvegostomig, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca and the tag pipeline.
Shares Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads), Capecitabine, Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, Capecitabine, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/